Yervoy (ipilimumab) is a prescription drug used to treat certain types of cancer, including melanoma and advanced renal cell carcinoma [1]. It is a biologic drug, which means it is derived from living organisms. According to the website Drug Patent Watch, the patent for Yervoy expired in 2016, which means that generic versions of the drug may now be available [1].

In terms of discounts for Yervoy, the Health Resources and Services Administration (HRSA) provides a program called the 340B Drug Pricing Program, which allows eligible healthcare organizations to purchase drugs at discounted prices [2]. However, it is unclear whether this program specifically applies to Yervoy or whether discounts are available for patients who have insurance.

A study published in JAMA Network Open in 2020 examined the cost of cancer drugs, including Yervoy, and found that the cost of these drugs has increased significantly over time [3]. The study authors noted that while some patients may be able to access financial assistance programs or discounts, these programs may not be sufficient to make the drugs affordable for all patients.

In conclusion, while there may be discounts available for Yervoy through the 340B Drug Pricing Program, it is unclear whether these discounts can be combined with insurance. Patients who are prescribed Yervoy should speak with their healthcare provider and/or their insurance company to determine what options are available to them for obtaining the drug at an affordable cost.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://www.hrsa.gov/opa
[3] https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779418